Intuitive Surgical drops $15m, inks collab dev and licensing deal in Broncus Medical Series A

Broncus Medical said today it raised $15 million in a Series A from robotic surgery giant Intuitive Surgical (NSDQ:ISRG). The investment comes in three parts, including the $15 million equity investment, a technology development collaborative agreement and a licensing deal that will put Broncus Medical’s intellectual properties in Sunnyvale, Calif.-based Intuitive’s hands. Broncus Medical is developing technologies focused on diagnostic and therapeutic lung procedures, and will use funds from the round to support continued development of its lung cancer tech, including clinical trials. The company is currently engaged in a post-market study exploring the performance of Broncus’ tech for total lung navigation procedures and tumor access. “We are delighted to build a relationship with an industry leader like Intuitive, that shares our vision of bringing greater visibility and precision to lung cancer diagnosis and treatment, in order to benefit patients,” Broncus Holding chair Michael Zhao said in a prepared statement. The company touted that it has combined the use of fused fluoroscopy, real-time bronchoscopy and virtual bronchoscopic navigation to provide 3D views within the lungs to improve accuracy and enable more accurate access to nodules for diagnosis and treatment. The post Intuitive Surgical drops $15m, inks collab dev and licensing deal in Broncus Medical Series A appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Imaging Respiratory Broncus Medical Intuitive Surgical Source Type: news

Related Links:

Johnson &Johnson’s Auris Health scored positive preliminary results from a first-in-human study evaluating the Monarch Platform to aid in the diagnosis of peripheral pulmonary lesions. Data from the BENEFIT study was presented at the American Thoracic Society 2019 Conference in Dallas. So far in BENEFIT, Monarch has been used in 24 patients to localize targeted nodules using a combination of direct visualization, navigational guidance and radial endobronchial ultrasound. The primary effectiveness endpoint, successful localization of targeted pulmonary lesions confirmed using a radial endobronchial ult...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news
Johnson &Johnson’s Ethicon is set to acquire Takeda Pharmaceutical’s Fibrin Sealant Patch for $400 million. The deal is set to close in the second half of 2019. The TachoSil is a surgical patch designed to achieve safe fast and reliable bleeding control. Upon close, about 80 employees will transition to Ethicon. Takeda said net sales for TachoSil were about $155 million for the 2018 fiscal year. Terms for the deal call for Ethicon to acquire the assets and licenses that support the manufacturing, licensing and commercialization of TachoSil, while Takeda maintains ownership of the man...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Peripheral pulmonary nodules are increasingly detected in patients screened for lung cancer or during disease progression of thoracic or extrathoracic malignancies. Sampling these lesions requires surgery, com...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Tags: Technical advance Source Type: research
Authors: Sato M, Murayama T, Nakajima J Abstract Anatomical segmentectomy is gathering increasing interest among thoracic surgeons because of increased detection of pulmonary nodules with ground-glass opacity (GGO) as well as an increase in the number of compromised patients. Accurate determination of intersegmental planes is a challenge in anatomical segmentectomy, and multiple methods have been proposed including developing inflation/deflation lines and injecting indocyanine green either intravenously or intrabronchially. Considering resection margins, adding a localization technique to conventional methods, or c...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
CONCLUSIONS: The LYU enables simultaneous imaging and phototherapy that allows accurate irradiation of peripheral lung cancers. This new laser device may enable ultra-minimally invasive transbronchial treatment of peripheral lung cancer. PMID: 31034817 [PubMed - as supplied by publisher]
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
Conclusion Diagnostic procedures should be chosen based on the clinical character in EBUS-TBNA negative patients with suspected lung cancer. Long time follow-up is very important in patients whose diagnosis is apparently unknown. 
 DOI: 10.3779/j.issn.1009-3419.2019.04.04
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Legal costs surrounding Johnson and Johnson’s talc baby power and its blood thinner Xarleto bogged down the healthcare giant’s 1Q19 earnings. But while earnings from the New Brunswick, NJ-based company were down 14% from a year earlier, the firm managed to beat analyst expectations. J&J posted income of $3.75 billion or $1.39 per share for 1Q19. In 1Q18, the company brought in $4.37 billion or $1.60 per share. As a result, the healthcare company changed its full-year earnings forecast to a range of $8.53 to $8.63 a share, down from its previous estimate of between $8.50 and $8.65. The fi...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Here, we report a case of advanced non ‐small‐cell lung cancer with a rare epidermal growth factor receptor (EGFR) exon 20 H773L/V774M compound mutation, which demonstrated poor clinical response to afatinib, a second‐generation EGFR‐TKI with pan‐human EGFR blocking activity. The anti‐cancer treatment was shifted to platinum‐ based chemotherapy, which resulted in a partial response. Uncommon mutations account for 10 –15% of epidermal growth factor receptor (EGFR) mutations in patients with non‐small‐cell lung cancer. Afatinib is currently the most efficient EGFR‐tyrosine kinase inhibitor (TKI) aga...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
Johnson &Johnson (NYSE:JNJ) said yesterday that its Ethicon biz completed its $3.4 billion acquisition of robotic surgery dev Auris Health and the $2.8 billion divestiture of its Advanced Sterilization Products to Fortive (NTSE:FTV). Redwood City, Calif.-based Auris Health, which was created by Intuitive Surgical (NSDQ:ISRG) founder and surgical robotics pioneer Dr. Fred Moll, developed and produces the robotic Monarch platform which has FDA clearance for diagnostic and therapeutic bronchoscopic procedures. The Monarch system features a controller interface for navigating the integrated flexible rob...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Featured Mergers & Acquisitions Robotics Sterilization / Calibration Wall Street Beat johnsonandjohnson Source Type: news
Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) assays are widely used for complementary or companion diagnostic purposes during treatment with immune checkpoint inhibitors. However, limited information is available on the clinical reliability of the PD-L1 IHC assay using small biopsy samples. Participants included 46 patients with nonsmall cell lung cancer who underwent PD-L1 testing using 3 PD-L1 IHC assays (22C3, SP142, and SP263) for both small biopsy samples and surgical specimens from November 2017 to June 2018. The PD-L1 IHC assay results were analyzed with cut-off values of 1%, 5%, 10%, and 50%. The P...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
More News: Bronchoscopy | Cancer | Cancer & Oncology | Clinical Trials | Lung Cancer | Respiratory Medicine | Study